Durect Corporation (DRRX) 1.88 $DRRX DURECT Corporation

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Durect Corporation (DRRX) 1.88 $DRRX

DURECT Corporation Invites You to Join its Second Quarter 2016 Earnings Conference Call
PR Newswire - Mon Jul 25, 4:29PM CDT
In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Monday, August 1, 2016 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
DRRX: 1.88 (-0.06)

DURECT's Abuse-Deterrent Opioid Poised for FDA Approval
Marketwire Canada - Thu Jul 14, 1:37PM CDT
SAN FRANCISCO, CA--(Marketwired - July 14, 2016) - Oxycodone is a powerful and lucrative painkiller, but one with serious downsides. Dependency on the opioid has become a major issue medically, politically and, most profoundly­­, for the patients whose addictions have become debilitating or fatal. DURECT Corp.'s Remoxy, an abuse-deterrent formulation of oxycodone, has an FDA approval date of Sept. 25, 2016, and may provide a safer alternative.
DRRX: 1.88 (-0.06)

DURECT to Present at the Jefferies Healthcare Conference
PR Newswire - Tue May 31, 7:30AM CDT
DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and Chief Executive Officer, will be presenting at the Jefferies Healthcare Conference on Friday, June 10 at 1:30 pm Eastern Time. The conference is being held at the Grand Hyatt Hotel in New York. Management will also be available for one-on-one meetings at this conference; interested institutional investors should request a one-on-one meeting through the conference coordinators.
DRRX: 1.88 (-0.06)

DURECT Announces FDA Advisory Committee Meeting for REMOXY®
PR Newswire - Thu May 19, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that an Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the REMOXY® New Drug Application (NDA), in a joint meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee tentatively scheduled for August 5, 2016. Pain Therapeutics also stated that the FDA advised them that the Prescription Drug User Fee Act (PDUFA) date for the REMOXY NDA of September 25, 2016 is unchanged.
DRRX: 1.88 (-0.06), PTIE: 2.73 (+0.03)

DURECT Announces New REMOXY® Data being Presented at American Pain Society Meeting
PR Newswire - Wed May 11, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced researchers will present new data around REMOXY's abuse-deterrent properties at the 35th Annual Scientific Meeting of the American Pain Society (APS) meeting. The scientific poster is titled "REMOXY: Human Abuse Potential Study of an Extended-Release Oxycodone Formulation." Co-authors Lynn Webster and Nadav Friedmann are scheduled to present the data at APS on Thursday, May 12, 2016, from 3:45 to 5:15 pm Central Time. This scientific poster will be available for review by the general public on DURECT's website at www.durect.com.
DRRX: 1.88 (-0.06), PTIE: 2.73 (+0.03)

Durect reports 1Q loss
Automated Insights - Thu May 05, 5:12PM CDT
CUPERTINO, Calif. (AP) _ Durect Corp. (DRRX) on Thursday reported a loss of $7.9 million in its first quarter.
DRRX: 1.88 (-0.06)

DURECT Corporation Announces First Quarter 2016 Financial Results and Update of Programs
PR Newswire - Thu May 05, 3:05PM CDT
DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2016. Total revenues were $3.6 million and net loss was $7.9 million for the three months ended March 31, 2016 as compared to total revenues of $4.8 million and net loss of $4.9 million for the three months ended March 31, 2015.
DRRX: 1.88 (-0.06)

DURECT Announces Closing of Public Offering of Common Stock
PR Newswire - Fri Apr 29, 11:15AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced the closing of an underwritten public offering of 13,800,000 shares of its common stock, offered at a price of $1.25 per share to the public, including 1,800,000 shares purchased by the underwriters pursuant to their option. All of the shares in the offering were sold by DURECT. The gross proceeds to DURECT from this offering were approximately $17.3 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by DURECT.
DRRX: 1.88 (-0.06)

DURECT Corporation Invites You to Join its First Quarter 2016 Earnings Conference Call
PR Newswire - Thu Apr 28, 3:30PM CDT
In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2016 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 5, 2016 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
DRRX: 1.88 (-0.06)

DURECT Announces Pricing of Public Offering of Common Stock
PR Newswire - Tue Apr 26, 8:00AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price of $1.25 per share to the public. The gross proceeds to DURECT from this offering are expected to be $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by DURECT. All of the shares in the offering are to be sold by DURECT. The offering is expected to close on or about April 29, 2016, subject to the satisfaction of customary closing conditions. DURECT has granted the underwriters a 30-day option to purchase up to an aggregate of 1,800,000 additional shares.
DRRX: 1.88 (-0.06)

DURECT Announces Proposed Public Offering of Common Stock
PR Newswire - Mon Apr 25, 3:01PM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that it is offering, subject to market conditions, shares of its common stock in an underwritten public offering. DURECT anticipates using the net proceeds from this offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs and to meet working capital needs. All of the shares in the offering are to be sold by DURECT.
DRRX: 1.88 (-0.06)

JonesTrading's George Zavoico Interviewed by The Life Sciences Report
Marketwired - Thu Apr 14, 8:02AM CDT
While the vagaries of the 2016 political season create uncertainty in the biotech and pharmaceutical sectors, companies are moving ahead with innovative cell therapies, gene therapies and new, safer ways to deliver addictive drugs, and investors find themselves in a position to play the development ideas with varying degrees of risk. In this interview with The Life Sciences Report, George Zavoico of Jones Trading Institutional Services explores how the presidential race could affect the biotech industry, and explains the growth prospects of three biotech names that could strike gold.
DRRX: 1.88 (-0.06)

DURECT Announces POSIMIR® Program Update
PR Newswire - Thu Apr 07, 4:00PM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that after the PERSIST Phase 3 trial for POSIMIR® was underway and enrolling patients at multiple sites, the Company received a letter from FDA advising the Company to make a number of amendments to the PERSIST trial. One of the recommendations was to incorporate standard bupivacaine HCl as an active control. The Company had a follow-up call with the FDA this week to discuss the advice letter, as a result of which the Company has decided to implement the FDA's recommendations. This change will add to the time and cost to complete the PERSIST trial, but the Company believes that a positive outcome from this trial design would result in a stronger NDA filing and potentially provide commercial advantages. The Company will provide an update on the impact to PERSIST once it has worked through the logistics of making this change. In the interim, the Company will continue enrollment under the existing protocol. As a point of reference, the Company notes that in cohort 2 of the BESST trial, which like PERSIST was in laparoscopic cholecystectomy patients, the control arm was also standard bupivacaine HCl and POSIMIR achieved a statistically significant pain reduction over 72 hours compared to the control when using the same statistical method being used in PERSIST.
DRRX: 1.88 (-0.06)

DURECT Announces Resubmission of REMOXY® New Drug Application to the U.S. Food and Drug Administration
PR Newswire - Tue Mar 29, 10:15AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced its licensee, Pain Therapeutics (Nasdaq: PTIE), has resubmitted the New Drug Application (NDA) for REMOXY® (oxycodone capsules CII) to the U.S. Food and Drug Administration (FDA). Pain Therapeutics has stated that they expect to be notified by the FDA of a Prescription Drug User Fee Act (PDUFA) action date within 30 days. The original REMOXY NDA has a Priority Review Designation.
DRRX: 1.88 (-0.06), PTIE: 2.73 (+0.03)

Biotech Sector Report Analyst Coverage Focusing on Upcoming FDA Decisions
ACCESSWIRE - Mon Mar 28, 7:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / DURECT Corporation (NASDAQ: DRRX), Genocea Biosciences Inc. (NASDAQ: GNCA), Flamel Technologies SA (NASDAQ: FLML), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
FLML: 12.68 (+0.17), VNDA: 11.72 (+0.32), GNCA: 4.09 (+0.02), DRRX: 1.88 (-0.06)

Laidlaw & Co. Analyst Jim Molloy Interviewed by The Life Sciences Report
Marketwired - Thu Mar 17, 8:01AM CDT
After a devastating start to 2016, biotech stocks have snapped back. Laidlaw & Co. analyst Jim Molloy likes the resurgence he's seeing in biotechnology share prices, but cautions that confirmation of a recovery will require cash-laden drug developers to begin acquiring smaller biotechs trading at depressed market valuations. In the meantime, Molloy says, individual and small institutional investors can still buy growth stories at bargain prices. In this interview with The Life Sciences Report, Molloy mentions three names with near-term catalysts that, with good data, can bring a needed lift to biotech portfolios.
CERC: 3.40 (-0.40), DRRX: 1.88 (-0.06)

DURECT Corp.'s CEO James E. Brown Interviewed by The Life Sciences Report
Marketwired - Tue Feb 02, 8:03AM CST
Alza Corp. was a pioneer in the field of drug delivery, and that illustrious heritage continues in its spinout, DURECT Corp. (NASDAQ: DRRX), which has leveraged the technology to enable highly innovative, value-added products that may soon be on the market. In this interview with The Life Sciences Report, DURECT cofounder and CEO James E. Brown discusses his company's pipeline, and how DURECT is evolving into a high-margin, blockbuster biotech.
JNJ: 125.18 (-0.05), DRRX: 1.88 (-0.06)

DURECT to Present at the BIO CEO & Investor Conference
PR Newswire - Thu Jan 28, 4:00PM CST
DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Monday, February 8 at 4:00 p.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City. Investors and analysts that are attending the conference may request a one-on-one meeting through the conference organizers at https://www.bio.org/events/conferences/bio-ce...rce-center.
DRRX: 1.88 (-0.06)

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxcczv/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Attention Deficit Hyperactivity Disorder (ADHD) Overview - Therapeutics Development - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - APeT Holding BV - Arbor Pharmaceuticals, LLC. - BCWorld Pharm Co. Ltd. - Collegium Pharmaceutical, Inc. - Curemark, LLC - Domain Therapeutics SA - DURECT Corporation - H. Lundbeck A/S - Heptares Therapeutics Limited - Highland Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Luc Therapeutics, Inc. - Medgenics Inc. - Merck & Co., Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Neurovance, Inc. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/jx...on_deficit
KMPH: 4.19 (-0.03), MDGN: 5.89 (+0.12), ADHD: 4.25 (-0.03), SUPN: 22.33 (+0.11), COLL: 12.19 (+0.06), DRRX: 1.88 (-0.06), NEOS: 9.03 (+0.20), NDRM: 18.68 (-0.13), MRK: 58.63 (-0.03), SHPG: 195.17 (+1.05), ITCI: 40.89 (+0.09)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 185

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 198

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 112

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 184

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 158

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 149

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 0

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 138

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading

Top 5 Most Recently Viewed Articles

Analysts Raise Price Targets for Agilent After Strong Earnings

Updated Category News Views 139

Agilent Technologies Inc Reports Impressive Fourth Quarter Results Agilent Technologies Inc (NYSE: A) celebrated a positive earnings surprise for its latest quarterly results, significantly surpassing forecasts and setting a promising tone for the year ahead. The company's earnings per share reached $1.59, edging out analyst expectations, which were set at $1.58 per...

Continue Reading
AstraZeneca's Historic NYSE Move Signals Market Shift

Updated Category News Views 53

AstraZeneca's Gigantic Leap In the hustle of Wall Street's whirring machine, June 5, 2026, dawned with a palpable buzz. Why? AstraZeneca (NYSE:AZN) just pulled off the biggest market cap transfer in the New York Stock Exchange's epic 234-year saga. Now that's a splash, not just a ripple. It’s like watching a giant whale breach in an already crowded ocean. But what does...

Continue Reading
Doughlicious Brings Irresistible Frozen Treats to Target Stores

Updated Category News Views 247

Doughlicious Expands Offerings into Target Stores Doughlicious, the celebrated brand born in London, is making waves across the United States as it announces its expansion into Target stores nationwide. Building on their successful U.S. launch at Whole Foods Market, the brand is excited to bring its crave-worthy frozen cookie dough and gelato bites to an even broader...

Continue Reading
Amber Grid Seeks New CEO: Selection Process Announced

Updated Category News Views 246

Amber Grid CEO Selection Process Initiated AB Amber Grid, with the legal entity code: 303090867, is located at Laisv?s ave. 10, LT-04215 Vilnius, Lithuania. As the current CEO's five-year tenure approaches its conclusion, the Board has officially announced the commencement of the selection process for the next CEO. Application Timeline and Processes Interested candidates...

Continue Reading
Vishay Precision Group Reports Third Quarter Results for FY24

Updated Category News Views 117

Vishay Precision Group Announces Q3 2024 Financial Results Vishay Precision Group, Inc. (NYSE: VPG), a recognized leader in precision measurement and sensing technologies, recently released its financial results for the third quarter of fiscal 2024, closing on September 28, 2024. The report highlights various metrics that provide insight into the company’s performance...

Continue Reading